Abstract PS11-10: A Phase 1b/2 Study of the BET inhibitor ZEN003694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations
Year: 2021
Type: conference-abstract
Source: Cancer Research
Authors: Philippe Aftimos, Mafalda Oliveira, Kevin Punie, Valentina Boni, Erika Hamilton, Ayca Gucalp, Payal Shah, Lida Mina, Priyanka Sharma, Lisa Bauman, Eric Campeau, Sarah Attwell, Margo Snyder, Karen Norek, Akos Czibere, Yanke Yu, Michael H Silverman, Sanjay Lakhotia, Susan Domchek, Jennifer Litton, Mark Robson
Institutions: Université Libre de Bruxelles, Institut Jules Bordet, Vall d'Hebron Institute of Oncology, Universitair Ziekenhuis Leuven, Sarah Cannon, Memorial Sloan Kettering Cancer Center, Abramson Cancer Center, University of Pennsylvania, Banner MD Anderson Cancer Center, The University of Kansas Cancer Center, Pfizer (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3133464435